Adrihal 50mg Injection

About

Adrihal 50mg Injection is a potent antineoplastic agent employed in the treatment of various aggressive cancers. Its mechanism of action involves a multi-faceted attack on cancer cells, primarily by intercalating into DNA and inhibiting topoisomerase II, which are critical for DNA replication and repair. This disruption leads to DNA strand breaks, chromosomal aberrations, and ultimately, the induction of apoptosis in rapidly dividing malignant cells. Administered intravenously, Adrihal achieves systemic distribution, making it effective against both primary tumors and metastatic disease. It is often integrated into comprehensive chemotherapy regimens to maximize therapeutic efficacy, reduce tumor burden, and improve the overall prognosis for patients with advanced malignancies.

Uses

• Treatment of various solid tumors.
• Management of certain hematological cancers.
• Adjuvant therapy after surgical removal of tumors.
• Palliative treatment for advanced or recurrent cancers.

Directions For Use

Adrihal 50mg Injection is administered intravenously by a qualified healthcare professional. The precise dosage, infusion rate, and treatment schedule will be determined by your doctor based on your specific medical condition and response to treatment.

Benefits

• Strong cytotoxic activity against a range of cancers.
• Effective in achieving significant tumor regression.
• Can improve disease-free and overall survival.
• A crucial component in multi-drug chemotherapy protocols.
• Offers a systemic approach to combat widespread cancer.
• May lead to substantial clinical responses and remission.

Side Effects

• Nausea and vomiting
• Fatigue and malaise
• Hair loss (alopecia)
• Myelosuppression
• Mucositis
• Diarrhea
• Cardiotoxicity
• Red urine discoloration
• Injection site reactions
• Anorexia
• Increased risk of infection
• Peripheral neuropathy

Safety Measures

• Alcohol - Avoid alcohol consumption as it may exacerbate liver toxicity, increase gastrointestinal side effects, and impair overall health during treatment.
• Pregnancy - Adrihal is contraindicated during pregnancy due to its potential for severe fetal harm and teratogenicity. Effective contraception is required for both male and female patients during and after treatment.
• Breastfeeding - Breastfeeding is not recommended during Adrihal treatment as the drug may be excreted into breast milk and could cause serious adverse effects in the nursing infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and regular liver function monitoring is crucial due to potential hepatotoxicity.
• Kidney - Caution is advised in patients with renal impairment; dose modifications may be required based on kidney function to prevent drug accumulation and increased toxicity.
• Lung - Monitor for signs of pulmonary toxicity, such as cough or shortness of breath, as some antineoplastic agents can cause interstitial lung disease or pneumonitis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.